About Rubedo Life Sciences
Rubedo Life Sciences is a biopharmaceutical company that is developing a diverse portfolio of innovative therapies that are engineered to target cells that are responsible for chronic age-related diseases. Its proprietary ALEMBIC drug discovery platform has generated novel first-in-class small molecules designed to selectively target senescent cells, which are important in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic diseases. The Rubedo leadership team is made up of industry leaders and pioneers in chemistry, technology, and life sciences, with extensive experience in drug development and commercialization ranging from large pharma to biotech innovators.
Open positions (3)
Company details
Funding
Total raised
$52M
Last stage
Series A
Investors
Founders
Marco Quarta
Scientist, entrepreneur, and biotechnology executive focused on aging and regenerative medicine. Previously led research at Stanford University's Center for Tissue Regeneration. Founding CEO of Rubedo (2018–2024), now CSO.
LinkedInMark Gallop
Veteran drug hunter, chemist, and serial entrepreneur. Former CSO at BlueLight Therapeutics and President at Light Horse Therapeutics. Expert in drug discovery in oncology, neuroscience, and GI disorders.
Julian Klein
Co-founder at Rubedo Life Sciences, based in the San Francisco Bay Area. Background in early-stage biotech and drug development.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.